Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

NCT03606512 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

NCT00316264 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

NCT00129766 ·Status: COMPLETED ·Phase: PHASE3

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

NCT00538785 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

NCT03333317 ·Status: TERMINATED ·Phase: PHASE2

Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.

NCT06856967 ·Status: RECRUITING

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

NCT02534935 ·Status: COMPLETED ·Phase: PHASE2

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

NCT03915366 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

NCT00667602 ·Status: COMPLETED ·Phase: PHASE3

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT07222384 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526 ·Status: COMPLETED ·Phase: PHASE3

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

NCT00780806 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

NCT00433914 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02890381 ·Status: TERMINATED ·Phase: PHASE1

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

NCT00798304 ·Status: TERMINATED ·Phase: PHASE2

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

NCT00721396 ·Status: COMPLETED ·Phase: PHASE2

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

NCT02531698 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

NCT04645966 ·Status: TERMINATED ·Phase: PHASE2

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

NCT00262002 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

NCT02692599 ·Status: COMPLETED ·Phase: PHASE3